NCT01643603 2020-12-17Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic MalignanciesBarbara Ann Karmanos Cancer InstitutePhase 1 Terminated5 enrolled
NCT01609816 2020-03-16Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin LymphomaBarbara Ann Karmanos Cancer InstitutePhase 1 Terminated8 enrolled
NCT00608361 2015-07-02Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryNational Cancer Institute (NCI)Phase 1 Completed80 enrolled